Long-acting muscarinic antagonists for the treatment of asthma in children—a new kid in town

被引：4
作者：
Hamelmann E. [1 ,2 ]
机构：
[1] Kinderzentrum Bethel, Evangelisches Klinikum Bethel, Grenzweg 10, Bielefeld
[2] Allergy Center of the Ruhr University, Bochum
来源：
Allergo Journal International | 2018年 / 27卷 / 7期
关键词：
Asthma; Children; Tiotropium; Treatment;
D O I：
10.1007/s40629-018-0066-y
中图分类号：
学科分类号：
摘要：
Background: Asthma is the most prevalent chronic airway disease observed in children and adolescents, yet the variety of treatment options available for this age group is limited. With many factors influencing therapeutic efficacy including patient knowledge, adherence, and therapy choice as well as delivery device, it is important to have more options to tailor to individual patient needs. Methods: This article is an overview of recent scientific articles using a systematic literature search in PubMed and specialist databases. Results: Tiotropium is the first long-acting muscarinic antagonist to be licensed for treatment of asthma and has been demonstrated to be an effective add-on therapy across all age groups. Its therapeutic success in clinical trials resulted in Food and Drug Administration and the European Medicines Agency approval for asthma treatment in people over the age of 6 years in the US and EU. Conclusion: Further studies into the use of tiotropium, especially in younger children, could be of interest for future treatment decisions. © 2018, The Author(s).
引用
收藏
页码：220 / 227
页数：7
相关论文
共 46 条
  • [1] Asher I., Pearce N., Global burden of asthma among children, Int J Tuberc Lung Dis, 18, pp. 1269-1278, (2014)
  • [2] Global strategy for asthma management and prevention, (2017)
  • [3] 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet Respir Med, 5, pp. 691-706, (2017)
  • [4] Anderson R., Gupta R., Kapetanakis V., Asher M.I., Clayton T., Robertson C.F., Et al., International correlations between indicators of prevalence, hospital admissions and mortality for asthma in children, Int J Epidemiol, 37, pp. 573-582, (2008)
  • [5] Et al., Guideline for the Diagnosis and Treatment of Asthma—Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology, Pneumologie, 71, pp. 849-919, (2017)
  • [6] (2017)
  • [7] Plaza Moral V., Alonso Mostaza S., Alvarez Rodriguez C., Gomez-Outes A., Gomez Ruiz F., Lopez Vina A., Et al., Spanish guideline on the management of asthma, J Investig Allergol Clin Immunol, 26, pp. 1-92, (2016)
  • [8] (2017)
  • [9] Expanded Indication for SPIRIVA® Respimat® for People 6 Years and Older, (2018)
  • [10] O'Byrne P.M., Pharmacologic interventions to reduce the risk of asthma exacerbations, Proc Am Thorac Soc, 1, pp. 105-108, (2004)
12345